Thalidomide-O-amido-C4-N3 is primarily utilized in targeted drug delivery systems, particularly in the development of proteolysis-targeting chimeras (PROTACs). Its structure allows it to act as a linker, connecting a target protein-binding ligand to an E3 ubiquitin ligase recruiter. This facilitates the degradation of specific proteins, making it valuable in cancer therapy and research. Additionally, it is explored in the treatment of diseases caused by protein misfolding or overexpression, such as neurodegenerative disorders and certain types of cancers. Its application extends to experimental studies aimed at understanding protein degradation pathways and developing novel therapeutic strategies.